Document and Entity Information
Document and Entity Information | Mar. 20, 2024 |
Cover [Abstract] | |
Amendment Flag | true |
Entity Central Index Key | 0001661998 |
Document Type | 8-K/A |
Document Period End Date | Mar. 20, 2024 |
Entity Registrant Name | HOMOLOGY MEDICINES, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38433 |
Entity Tax Identification Number | 47-3468154 |
Entity Address, Address Line One | One Patriots Park |
Entity Address, City or Town | Bedford |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 01730 |
City Area Code | (781) |
Local Phone Number | 301-7277 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.0001 par value per share |
Trading Symbol | FIXX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | On March 20, 2024, Homology Medicines, Inc. filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Initial 8-K”) to report the 1-for-18 reverse stock split. This Form 8-K/A amends the Initial 8-K to (i) update the date that the reverse stock split will become effective and (ii) disclose that the initial listing application with respect to the continued listing of Homology common stock on The Nasdaq Global Market, as required by Nasdaq Stock Market Rule 5110(a), has been approved. |